You know how sometimes people say, Oh, it's okay. You don't have to read the first book in this series to dive right into the second. This is not that kind of book. You know how sometimes people say, ...

Your support goes further this holiday season. When you buy an annual membership or give a one-time contribution, we’ll give a membership to someone who can’t afford access. It’s a simple way for you ...

Councils in London are under pressure to follow Harrow ’s policy of one hour free parking. Senior Conservative Bob Blackman, ...

Harrow recently experienced a 24% share price increase over the last quarter, coinciding with its announcement of a $250 million debt financing via senior unsecured notes. This announcement comes at a ...

In late September 2025, Harrow, Inc. launched the Harrow Access for All (HAFA) program, expanding affordable and predictable pricing for its full portfolio of branded, generic, and compounded ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2024. The ...

Please provide your email address to receive an email when new articles are posted on . Byooviz references Lucentis, and Opuviz references Eylea. Harrow expects the transaction to be completed by the ...

There are concerns about the risks of setting fireworks off in the street A Harrow resident has claimed this has been the "worst year" he has experienced for fireworks being used in a dangerous or ...

IHEEZO™ Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly 14 ...

Harrow, Inc. (NASDAQ:HROW) achieved its first revenue in 2015 as an ophthalmic compounding pharmacy and now dominates this tiny niche with a roughly 35% share, perhaps 10 times the size of its nearest ...